Last reviewed · How we verify

Investigational sIPV — Competitive Intelligence Brief

Investigational sIPV (Investigational sIPV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine Poliovirus types 1, 2, and 3 Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Investigational sIPV (Investigational sIPV) — Sinovac Biotech Co., Ltd. sIPV is an inactivated poliomyelitis vaccine that stimulates immune responses against poliovirus types 1, 2, and 3 to prevent poliomyelitis infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Investigational sIPV TARGET Investigational sIPV Sinovac Biotech Co., Ltd phase 3 Inactivated viral vaccine Poliovirus types 1, 2, and 3
sIPV batch 3 sIPV batch 3 Institute of Medical Biology, Chinese Academy of Medical Sciences marketed Inactivated viral vaccine Poliovirus types 1, 2, and 3
1wIPV+2sIPV 1wIPV+2sIPV Sinovac Biotech Co., Ltd marketed Inactivated polio vaccine (IPV) Poliovirus types 1, 2, and 3 antigens
2wIPV+1sIPV 2wIPV+1sIPV Sinovac Biotech Co., Ltd marketed Inactivated viral vaccine Poliovirus types 1, 2, and 3 antigens
fIPV (0.1 mL) ID fIPV (0.1 mL) ID Centers for Disease Control and Prevention marketed vaccine poliovirus types 1, 2, and 3 antigens
oral polio vaccine + information oral polio vaccine + information Bandim Health Project marketed Live attenuated vaccine Poliovirus types 1, 2, and 3
DTacP-IPV combined vaccine (TETRAXIM™) DTacP-IPV combined vaccine (TETRAXIM™) Sanofi marketed Combination inactivated vaccine Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

  1. Sinovac Biotech Co., Ltd · 9 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
  3. GlaxoSmithKline · 5 drugs in this class
  4. Valneva Austria GmbH · 4 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Centers for Disease Control and Prevention · 3 drugs in this class
  7. China National Biotec Group Company Limited · 2 drugs in this class
  8. Statens Serum Institut · 2 drugs in this class
  9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
  10. Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Investigational sIPV — Competitive Intelligence Brief. https://druglandscape.com/ci/investigational-sipv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: